Figure 6.
The timing and severity of CRS, CRS-related treatment, and increases in serum ferritin and IL-6 levels after CT103A infusion. (A) The timing of CRS onset, grades, and durations are shown in lines with different colors for each patient. Magenta and blue ticks indicate treatment of tocilizumab and steroids, respectively. (B) A heatmap of the serum ferritin and IL-6 levels in 18 patients in the first month after CT103A infusion. Each block is composed of cells that represent the serum ferritin or IL-6 level collected at baseline and serial time point after infusion. The color of each cell is determined by the value (log10) of the serum ferritin or IL-6 level from low (black) to high (red). The elevation of serum ferritin and IL-6 levels seem parallel with the CRS grade. The peak of IL-6 seems slightly earlier than that of ferritin in most patients.

The timing and severity of CRS, CRS-related treatment, and increases in serum ferritin and IL-6 levels after CT103A infusion. (A) The timing of CRS onset, grades, and durations are shown in lines with different colors for each patient. Magenta and blue ticks indicate treatment of tocilizumab and steroids, respectively. (B) A heatmap of the serum ferritin and IL-6 levels in 18 patients in the first month after CT103A infusion. Each block is composed of cells that represent the serum ferritin or IL-6 level collected at baseline and serial time point after infusion. The color of each cell is determined by the value (log10) of the serum ferritin or IL-6 level from low (black) to high (red). The elevation of serum ferritin and IL-6 levels seem parallel with the CRS grade. The peak of IL-6 seems slightly earlier than that of ferritin in most patients.

Close Modal

or Create an Account

Close Modal
Close Modal